What is the likely cause and recommended work‑up for a 31‑year‑old man with recurrent left‑sided facial twitching and intermittent slurred speech persisting for three years after a COVID‑19 infection?

Recurrent Left-Sided Facial Twitching and Slurred Speech Post-COVID-19

This 31-year-old man requires urgent neurological evaluation for post-COVID-19 neurological sequelae, with primary consideration of hemifacial spasm versus focal motor seizures, and mandatory workup to exclude Guillain-Barré syndrome variants, Bell's palsy complications, or central nervous system involvement.

Clinical Context and Differential Diagnosis

The three-year persistence of recurrent left-sided facial twitching with intermittent slurred speech following COVID-19 infection represents a chronic neurological manifestation that differs from typical post-acute COVID-19 sequelae (PASC), which are generally defined as symptoms persisting beyond 4-12 weeks 1. However, the temporal association with COVID-19 and the specific symptom pattern warrant systematic investigation.

Key Distinguishing Features to Assess:

Facial twitching characteristics:

• Hemifacial spasm pattern: Involuntary, intermittent contractions starting periocularly and spreading to lower face, worsened by stress or fatigue
• Focal motor seizure pattern: Stereotyped movements, possible march to other body parts, associated altered awareness
• Myoclonic jerks: Brief, shock-like movements that may indicate subcortical origin 2

Slurred speech (dysarthria) timing:

• Concurrent with facial twitching (suggests focal seizure or brainstem involvement)
• Independent episodes (suggests separate pathology or bulbar involvement)
• Progressive versus episodic pattern

Recommended Diagnostic Workup

Tier 1 - Immediate Neurological Assessment:

1. Brain MRI with and without contrast focusing on:

   • Brainstem lesions (particularly facial nerve nucleus and corticobulbar tracts)
   • Demyelinating lesions
   • Vascular malformations or compression at cerebellopontine angle
   • Post-infectious inflammatory changes 3

2. Electroencephalogram (EEG) with video monitoring during symptomatic episodes:

   • Rule out focal seizures originating from motor cortex
   • Assess for epileptiform discharges
   • Note: Absence of EEG-EMG correlation suggests subcortical origin 2

3. Electromyography (EMG) of facial muscles:

   • Identify synchronized bursts concurrent with visible twitching
   • Differentiate hemifacial spasm from myokymia or fasciculations
   • Assess for denervation patterns suggesting peripheral nerve pathology 2

4. Nerve conduction studies including:

   • Facial nerve conduction bilaterally
   • Blink reflex studies
   • Assessment for demyelinating polyneuropathy patterns (GBS variants can present atypically) 4, 5

Tier 2 - If Initial Workup Suggests Post-Infectious Etiology:

1. Lumbar puncture with cerebrospinal fluid analysis:

   • Cell count, protein, glucose
   • Albuminocytological dissociation (elevated protein with normal cell count) suggests GBS variant 5
   • Anti-GQ1b antibodies if Miller Fisher syndrome suspected 6
   • SARS-CoV-2 PCR (though unlikely positive at 3 years) 3

2. Comprehensive autoimmune/inflammatory panel:

   • Anti-neuronal antibodies (NMDA, VGKC, GAD65)
   • Inflammatory markers (ESR, CRP)
   • Complement levels
   • Antinuclear antibodies

Tier 3 - Cardiovascular and Autonomic Assessment:

Given PASC can involve dysautonomia 1:

1. 10-minute active stand test for orthostatic vital signs
2. Ambulatory cardiac monitoring if palpitations or syncope present
3. Echocardiogram if cardiac symptoms coexist

Most Likely Diagnoses and Management

Primary Consideration: Hemifacial Spasm with Bulbar Involvement

If imaging shows vascular compression or structural lesion:

• Neurosurgical consultation for microvascular decompression consideration
• Trial of carbamazepine 200-400 mg twice daily or gabapentin 300-900 mg three times daily
• Botulinum toxin injections for symptomatic relief (every 3-4 months)

Secondary Consideration: Post-COVID-19 Focal Motor Seizures

If EEG demonstrates epileptiform activity:

• Initiate levetiracetam 500 mg twice daily, titrate to 1000-1500 mg twice daily
• Alternative: lamotrigine with slow titration (25 mg daily, increase by 25 mg every 2 weeks)
• Neurology follow-up for seizure management

Tertiary Consideration: Atypical GBS Variant or Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Bilateral facial weakness with paresthesias represents a rare GBS subtype associated with SARS-CoV-2 4. Though your patient has unilateral symptoms, atypical presentations occur.

If nerve conduction studies show demyelination and CSF shows albuminocytological dissociation:

• Intravenous immunoglobulin (IVIG) 2 g/kg divided over 2-5 days 5, 6
• Methylprednisolone 1 g IV daily for 3-5 days if IVIG insufficient 2
• Monitor for treatment resistance (first documented case of MFS resistant to IVIG was post-COVID) 6

Post-Infectious Myoclonus-Ataxia Syndrome

If EMG shows subcortical origin with absent somatosensory evoked potentials 2:

• Aggressive early immunotherapy is critical: IV methylprednisolone 1 g daily for 5 days
• Add clonazepam 0.5-2 mg three times daily for myoclonus suppression
• Consider IVIG if steroid response inadequate

Critical Pitfalls to Avoid

1. Do not dismiss chronic symptoms as purely psychiatric: Post-COVID neurological manifestations can persist beyond typical PASC timeframes and require organic workup 7

2. Do not assume Bell's palsy without excluding central causes: Facial weakness post-COVID requires imaging to exclude stroke, demyelination, or mass lesions 8, 9, 10

3. Do not delay immunotherapy if inflammatory etiology suspected: Early aggressive treatment with steroids or IVIG correlates with favorable outcomes in post-infectious neurological syndromes 2

4. Do not overlook bilateral involvement: Even if symptoms appear unilateral, examine and test both sides—COVID-associated facial palsy has higher rates of bilateral involvement than typical Bell's palsy 9

5. Do not attribute all symptoms to COVID without excluding other causes: Maintain broad differential including structural lesions, autoimmune conditions, and metabolic disorders 1, 3

Prognosis and Follow-up

• Isolated facial nerve palsy post-COVID: 67% achieve complete recovery within median 11 days with treatment 9
• GBS variants: Variable recovery; some patients show persistent deficits despite IVIG 6
• Myoclonus-ataxia syndrome: Good outcomes with early immunotherapy; 2-month follow-up typically shows significant improvement 2
• Chronic symptoms (3 years): Suggest either inadequately treated inflammatory process, structural pathology, or established neurological damage requiring symptomatic management

Mandatory neurology referral within 1-2 weeks for comprehensive evaluation and treatment initiation. The combination of motor (facial twitching) and bulbar (dysarthria) symptoms with chronic persistence demands urgent investigation to prevent further neurological deterioration.